INmune Bio Inc. (INMB)
NASDAQ: INMB
· Real-Time Price · USD
2.05
0.02 (0.99%)
At close: Sep 26, 2025, 10:59 AM
0.99% (1D)
| Bid | 2.04 |
| Market Cap | 54.5M |
| Revenue (ttm) | 50K |
| Net Income (ttm) | -55.51M |
| EPS (ttm) | -2.59 |
| PE Ratio (ttm) | -0.79 |
| Forward PE | -1.37 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.05 |
| Volume | 74,649 |
| Avg. Volume (20D) | 3,346,717 |
| Open | 2.02 |
| Previous Close | 2.03 |
| Day's Range | 2.01 - 2.08 |
| 52-Week Range | 1.71 - 11.64 |
| Beta | 1.04 |
| Ex-Dividend Date | n/a |
About INMB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol INMB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for INMB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+1.09%
INmune Bio shares are trading lower after the comp...
Unlock content with
Pro Subscription
1 month ago
+11.72%
INmune Bio shares are trading higher after the company announced its INKmune Phase I/II trial met its primary and secondary endpoints.
1 month ago · fool.com
INmune Bio (INMB) Q2 Loss Widens 110%INmune Bio (INMB) Q2 Loss Widens 110%
2 months ago · seekingalpha.com
INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer'sINmune Bio's XPro missed its Phase II primary endpoint, but subgroup data and safety profile suggest potential for targeted Alzheimer's patients with neuroinflammation. Despite the setback, I see sign...
2 months ago · proactiveinvestors.com
INmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trialINmune Bio Inc (NASDAQ:INMB) shares plummeted almost 60% following disappointing results from a Phase 2 clinical trial of its experimental Alzheimer's drug, XPro. The drug failed to meet the primary c...
